Where Aquestive Therapeutics Stands With Analysts
Portfolio Pulse from Benzinga Insights
Analysts have provided bullish ratings for Aquestive Therapeutics (NASDAQ:AQST) in the last quarter, with no bearish or indifferent ratings. The average 12-month price target for AQST is $5.33, which has increased by 6.6% over the past month.
November 08, 2023 | 7:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts are bullish on AQST with an average 12-month price target of $5.33, which has increased by 6.6% over the past month.
The bullish ratings and increasing price target indicate a positive outlook for AQST. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100